hydroxychloroquine has been researched along with sirolimus in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 15 (65.22) | 24.3611 |
| 2020's | 7 (30.43) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
| Lübbe, J; Malé, PJ; Masouyé, I; Saurat, JH; Sorg, O | 1 |
| Chen, N; Debnath, J; Eritja, N; Lock, R | 1 |
| Digumarthy, S; Fidias, P; Goldberg, SB; Heist, RS; Lynch, TJ; McCarthy, PO; Muzikansky, A; Neal, JW; Sequist, LV; Settleman, JE; Sharma, S; Shaw, AT; Supko, JG; Temel, JS | 1 |
| Mehnert, JM; White, EP; Xie, X | 1 |
| Alavi, A; Algazy, KM; Amaravadi, RK; Chang, YC; Davis, LE; DeMichele, AM; Evans, TL; Fecher, LA; Heitjan, DF; Hu, J; Kaiser, J; O'Dwyer, PJ; Panosian, JT; Pontiggia, L; Rangwala, R; Redlinger, M; Schuchter, LM; Tan, KS; Torigian, DA; Troxel, AB; Vaughn, DJ | 1 |
| Amaravadi, RK; Boyiadzis, M; Johnson, DE; Konig, H; Lotze, MT; Sehgal, AR; Tang, D | 1 |
| Chi, KH; Chi, MS; Kao, SJ; Ko, HL; Lee, CY; Yang, KL | 1 |
| Chen, YK; Chi, KH; Chi, MS; Chung, CH; Huang, SC; Ko, HL; Lee, CY; Liao, KW; Yang, KL | 1 |
| Huang, K; Liu, D | 1 |
| Erkan, D; Unlu, O | 1 |
| Bagwe, S; Bienfang, D; Cui, Y; El-Chemaly, S; Goldberg, HJ; Haughey, M; Henske, EP; Jones, AM; Julien-Williams, P; Maurer, R; Moss, J; Peters, E; Rosas, IO; Taveira-Dasilva, A; Villalba, JA | 1 |
| Arachchillage, DRJ; Laffan, M | 1 |
| Ferguson, TA; Frontera, E; Jia, L; Khan, NW; Klionsky, DJ; Qiu, Y; Thompson, DA; Yao, J; Zacks, DN | 1 |
| Bagwe, S; Cui, Y; El-Chemaly, S; Goldberg, HJ; Henske, EP; Lamattina, AM; Moss, J; Rosas, IO; Taveira-Dasilva, A | 1 |
| Gao, Y; He, Z; Shang, C; Wan, H; Xie, T; Xing, S; Xu, Q | 1 |
| Chen, YC; Chi, KH; Chiang, HC; Hsu, SPC; Huang, CC; Huang, YC; Wang, HE; Wang, YS | 1 |
| Chen, S; Ji, Y; Luo, M; Wang, Q; Xiang, B | 1 |
| Chhabra, R; Nanjundan, M | 1 |
| Ishibashi, Y; Kaji, Y; Nakamura, O; Negayama, T; Nomura, Y; Yamamoto, T | 1 |
| Andrade, MF; Bowers, RR; Delaney, JR; Jones, CM; Voelkel-Johnson, C; White-Gilbertson, S | 1 |
| Abraham, NG; Alcalai, R; Arad, M; Hochhauser, E; Petrover, Z; Seidman, CE; Seidman, J; Shainberg, A; Waldman, M; Yadin, D | 1 |
5 review(s) available for hydroxychloroquine and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia.
Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Survival; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gene Expression; HMGB1 Protein; Humans; Hydroxychloroquine; Leukemia; Leukocytes; Lysosomes; Phagosomes; Pyrazines; Sirolimus | 2015 |
Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease.
Topics: Antibodies, Monoclonal, Humanized; Antiphospholipid Syndrome; Antirheumatic Agents; Catastrophic Illness; Humans; Hydroxychloroquine; Immunosuppressive Agents; Patient Care Team; Plasma Exchange; Platelet Aggregation Inhibitors; Polydeoxyribonucleotides; Rituximab; Sirolimus | 2017 |
Pathogenesis and management of antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Autoantibodies; beta 2-Glycoprotein I; Complement Inactivator Proteins; Enzyme Inhibitors; Female; Forecasting; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Pregnancy; Pregnancy Complications; Rituximab; Sirolimus; Thrombosis | 2017 |
The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Everolimus; Humans; Hydroxychloroquine; Hyperlipidemias; Lymphangioleiomyomatosis; Prospective Studies; Sirolimus; Stomatitis; Treatment Outcome | 2020 |
5 trial(s) available for hydroxychloroquine and sirolimus
| Article | Year |
|---|---|
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Everolimus; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Sirolimus; Tissue Distribution | 2012 |
Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Hydroxychloroquine; Male; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Vacuoles | 2014 |
Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Blood Glucose; Drug Administration Schedule; Exanthema; Female; Fluorodeoxyglucose F18; Humans; Hydroxychloroquine; Male; Middle Aged; Nausea; Positron-Emission Tomography; Sarcoma; Sirolimus; Treatment Outcome; Tumor Burden; Young Adult | 2015 |
Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.
Topics: Adult; Aged; Autophagy; Diarrhea; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Forced Expiratory Volume; Headache; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lymphangioleiomyomatosis; Middle Aged; Mucositis; Sirolimus; Treatment Outcome; Vascular Endothelial Growth Factor D; Vital Capacity; Walk Test | 2017 |
Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.
Topics: Acetyl-CoA Carboxylase; Adult; Biomarkers; Correlation of Data; Drug Monitoring; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fibrinogen; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lung Diseases; Lymphangioleiomyomatosis; Respiratory Function Tests; Sirolimus; Vascular Endothelial Growth Factor Receptor-3 | 2018 |
13 other study(ies) available for hydroxychloroquine and sirolimus
| Article | Year |
|---|---|
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Sirolimus-induced inflammatory papules with acquired reactive perforating collagenosis.
Topics: Acneiform Eruptions; Anti-Inflammatory Agents; Collagen; Collagen Diseases; Drug Eruptions; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Liver Transplantation; Middle Aged; Sebaceous Glands; Sebum; Sirolimus; Skin | 2008 |
Autophagy restricts proliferation driven by oncogenic phosphatidylinositol 3-kinase in three-dimensional culture.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Autophagy; Cell Culture Techniques; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Humans; Hydroxychloroquine; Lysosomes; Mechanistic Target of Rapamycin Complex 1; Mitogen-Activated Protein Kinases; Multiprotein Complexes; Mutation; Phosphatidylinositol 3-Kinase; Sequestosome-1 Protein; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma.
Topics: Allosteric Regulation; Animals; Autophagy; Autophagy-Related Protein 7; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Synergism; Gene Knockdown Techniques; Humans; Hydroxychloroquine; Male; Melanoma; Mice; Mice, Nude; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes | 2013 |
Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
Topics: Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Pilot Projects; Salvage Therapy; Sirolimus; Treatment Outcome | 2015 |
Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein 5; Beclin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Hydroxychloroquine; RNA, Small Interfering; Sirolimus; Tongue Neoplasms; Up-Regulation | 2016 |
Inhibiting autophagy reduces retinal degeneration caused by protein misfolding.
Topics: Animals; Autophagy; Autophagy-Related Protein 5; Beclin-1; Hydroxychloroquine; Mice, Inbred C57BL; Mutation; Photoreceptor Cells, Vertebrate; Proteasome Endopeptidase Complex; Protein Folding; Proteolysis; Retinal Degeneration; Rhodopsin; Sirolimus | 2018 |
Lipopolysaccharide promotes lung fibroblast proliferation through autophagy inhibition via activation of the PI3K-Akt-mTOR pathway.
Topics: Animals; Autophagy; Cell Proliferation; Cells, Cultured; Chromones; Fibroblasts; Hydroxychloroquine; Lipopolysaccharides; Lung; Mice, Inbred C57BL; Morpholines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2019 |
Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Polarity; Cells, Cultured; Female; Glioblastoma; Humans; Hydroxychloroquine; Macrophages; Mice; Mice, Inbred C57BL; Programmed Cell Death 1 Receptor; Sirolimus | 2020 |
Lysophosphatidic acid reverses Temsirolimus-induced changes in lipid droplets and mitochondrial networks in renal cancer cells.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Hydroxychloroquine; Kidney Neoplasms; Lipid Droplets; Lysophospholipids; Mitochondria; Phosphoric Diester Hydrolases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2020 |
Rapalink-1 and Hydroxychloroquine Exhibit an Additive Effect in Undifferentiated Pleomorphic Sarcoma by Inducing Apoptosis.
Topics: Apoptosis; Autophagy; Cell Proliferation; Enzyme Inhibitors; Humans; Hydroxychloroquine; Sarcoma; Sirolimus; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2021 |
Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs).
Topics: Apoptosis; Autophagy; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Docetaxel; Female; Giant Cells; Humans; Hydroxychloroquine; Nelfinavir; Ovarian Neoplasms; Polyploidy; Sirolimus | 2022 |
Autophagy guided interventions to modify the cardiac phenotype of Danon disease.
Topics: Animals; Autophagy; Bortezomib; Cardiomegaly; Cardiomyopathies; Glycogen Storage Disease Type IIb; Humans; Hydroxychloroquine; Mice; Phenotype; Proteasome Endopeptidase Complex; Sirolimus | 2022 |